Webinar: What´s hot in immuno-oncology licensing


Event Details


 Find link to previous webinar on this topic here.
Dear Sir or Madam,

Join us for the continuation of the discussion from October 6’s live web panel. Hosted by LES, ShareVault, Defined Health, Pullan Consulting, The Trout Goup and the Biotechnology Industry Organization (BIO), this sequel will continue to discuss what’s exciting and not so exciting in immuno-oncology drug development, and why.

Even More of What’s Hot in
Immuno-Oncology Licensing
Thursday, December 10,
11:00am-12:15pm PST US

Register here

Biotech licensing and pharmaceutical business development consultant Linda Pullan will again be joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm. The panelists will start off by summarizing their previous discussion and recapping the main points. The topics that will be covered in the continued discussion include:

  • Cell Recruitment
  • Innate Immunity
  • Other Approaches
  • Licensing Criteria
  • Biomarkers
  • Strategy
  • Deal Terms
  • And more…

The panelists will also respond to questions from the audience.

If you are developing an immuno-oncology drug or working toward in- or out-licensing one, you will want to hear these perspectives.

About ShareVault:

Thousands of companies in more than 46 countries have depended on ShareVault, the industry leader in secure document sharing solutions. ShareVault combines the speed and simplicity of a cloud-based document sharing solution with the security and reliability of a virtual data room.

To find out more, download the white paper, “The Seven Habits of Highly Effective Data Rooms.”

Don’t Miss the 18th Annual BIO CEO & Investor Conference

Hear from Adaptimmune, Cellectis, Novartis, OncoMed, and many other oncology-related companies, plus expert panels on deal-making best practices at the largest independent, investor conference focused on established and emerging publicly traded and select private biotech companies.

Please join us February 8-9 in New York.

Register today!

About LES:

LES (USA & Canada) represents a highly diverse community of nearly 4,000 IP, business development and technology professionals that collaborate across multiple industries to create a unique networking and learning environment.

Learn More

About Defined Health

Defined Health is a leading business development strategy consulting firm. We’ve been assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.

Learn More

About The Trout Group

Trout is the leading strategic partner to the life sciences industry, connecting companies, investors and the most exciting innovations in the sector. With a unique suite of services in investor relations, communications and financial advisory, Trout is at the intersection through which scientific advances and its network of powerful relationships can meet to create long term value for stakeholders. Please join us at our Annual 1×1 Management Access Event in San Francisco, January 11-14, 2016.

About the Panelists:

Linda Pullan, Ph.D
Pullan Consulting

Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience.

Jeff Bockman, Ph.D
Vice President, Defined Health
Jeff leads the Oncology and Virology Practices at Defined Health. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.For more information about Jeff, click here.
Ferran Prat, Ph.D
VP of Strategic Industry Ventures, MD Anderson
Ferran helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners.For more information about Ferran, click here.
Axel Hoos, MD, Ph.D
Vice President, Oncology R&D and Head of Immuno-Oncology at GlaxoSmithKline Pharmaceuticals (GSK)
Axel builds the immuno-oncology portfolio of GSK across the modalities of antibodies, small molecules, bispecific molecules and cell & gene therapies, for which he directs clinical and discovery research.For more information about Axel, click here.
Nate Sanburn, MS
Director, Strategy and Business Development – Oncology, Eli Lilly & Company
Nathan Sanburn currently serves as the Strategy and Business Development Director for the Oncology Business Unit at Lilly. He is a molecular biologist by training, with over 19 years of experience across R&D, clinical trials, and business transactions.
Print This Post